Original Communication| Volume 155, ISSUE 4, P650-658, April 2014

Download started.


Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification

Published:November 25, 2013DOI:


      Neuroendocrine carcinomas (NECs) arising in the large intestine are rare neoplasms with highly aggressive behavior. The aim of the study was to compare the 2000 and 2010 World Health Organization (WHO) classification of these colorectal NECs.


      We conducted a retrospective study of patients diagnosed with colorectal NECs according to the WHO 2000 classification who underwent surgery at the Asan Medical Center between May 2000 and December 2010. The data were reevaluated to assess their consistency with the WHO 2010 classification.


      For 20 of the 34 patients (59%), the 2000 and 2010 WHO classifications yielded the same NEC diagnosis (NEC group), whereas for 14 of the 34 patients (41%), the WHO 2010 classification mandated a diagnosis of G1 or G2 neuroendocrine tumors (NETs) rather than NECs (G1/G2 NET group). The NEC group was older than the G1/G2 NET group (64 vs 55 years; P = .05). Tumor differentiation in the NEC group was poorer than in the G1/G2 NET group (percentage of poorly differentiated tumor, 70% vs 7%; P < .001). In both groups based on the 7th American Joint Committee on Cancer staging, most of the tumors were advanced at the time of diagnosis, reaching stage IIIB (6 NEC vs 10 NET) and stage IV (10 NEC vs 3 NET). The 5-year overall survival in the 2 groups was different (P = .02), but not the 5-year disease-free survival (P = .24).


      These results indicate that the WHO 2010 classification of colorectal NEC is more accurate and has better prognostic value than the WHO 2000 classification.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Modlin I.M.
        • Oberg K.
        • Chung D.C.
        • Jensen R.T.
        • de Herder W.W.
        • Thakker R.V.
        • et al.
        Gastroenteropancreatic neuroendocrine tumours.
        Lancet Oncol. 2008; 9: 61-72
        • Bernick P.E.
        • Klimstra D.S.
        • Shia J.
        • Minsky B.
        • Saltz L.
        • Shi W.
        • et al.
        Neuroendocrine carcinomas of the colon and rectum.
        Dis Colon Rectum. 2004; 47: 163-169
        • Khansur T.K.
        • Routh A.
        • Mihas T.A.
        • Underwood J.A.
        • Smith G.F.
        • Mihas A.A.
        Syndrome of inappropriate ADH secretion and diplopia: oat cell (small cell) rectal carcinoma metastatic to the central nervous system.
        Am J Gastroenterol. 1995; 90: 1173-1174
        • Hung S.S.
        Small cell carcinoma of the colon. A case report and literature review.
        J Clin Gastroenterol. 1989; 11: 335-339
        • Rindi G.
        • Arnold R.
        • Bosman F.
        Nomenclature and classification of neuroendocrine neoplasms of the digestive system.
        in: Bosman F.T. Carneiro F. Hruban R.H. WHO classification of tumours of the digestive system. IARC Press, Lyon2010: 13-14
        • Hamilton S.R.
        • Aaltonen L.A.
        World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system.
        IARC Press, Lyon2000
        • Tsikitis V.L.
        • Wertheim B.C.
        • Guerrero M.A.
        Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis.
        J Cancer. 2012; 3: 292-302
        • Gaffey M.J.
        • Mills S.E.
        • Lack E.E.
        Neuroendocrine carcinoma of the colon and rectum. A clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases.
        Am J Surg Pathol. 1990; 14: 1010-1023
        • Saclarides T.J.
        • Szeluga D.
        • Staren E.D.
        Neuroendocrine cancers of the colon and rectum. Results of a ten-year experience.
        Dis Colon Rectum. 1994; 37: 635-642
        • Staren E.D.
        • Gould V.E.
        • Jansson D.S.
        • Hyser M.
        • Gooch G.T.
        • Economou S.G.
        Neuroendocrine differentiation in “poorly differentiated” colon carcinomas.
        Am Surg. 1990; 56: 412-419
        • DiSario J.A.
        • Burt R.W.
        • Kendrick M.L.
        • McWhorter W.P.
        Colorectal cancers of rare histologic types compared with adenocarcinomas.
        Dis Colon Rectum. 1994; 37: 1277-1280
        • Hemminki K.
        • Li X.
        Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden.
        Cancer. 2001; 92: 2204-2210
        • Modlin I.M.
        • Sandor A.
        An analysis of 8305 cases of carcinoid tumors.
        Cancer. 1997; 79: 813-829
        • Jung K.W.
        • Park S.
        • Kong H.J.
        • Won Y.J.
        • Lee J.Y.
        • Seo H.G.
        • et al.
        Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009.
        Cancer Res Treat. 2012; 44: 11-24
        • Jetmore A.B.
        • Ray J.E.
        • Gathright Jr., J.B.
        • McMullen K.M.
        • Hicks T.C.
        • Timmcke A.E.
        Rectal carcinoids: the most frequent carcinoid tumor.
        Dis Colon Rectum. 1992; 35: 717-725
        • Shields C.J.
        • Tiret E.
        • Winter D.C.
        Carcinoid tumors of the rectum: a multi-institutional international collaboration.
        Ann Surg. 2010; 252: 750-755
        • Moore J.R.
        • Greenwell B.
        • Nuckolls K.
        • Schammel D.
        • Schisler N.
        • Schammel C.
        • et al.
        Neuroendocrine tumors of the rectum: a 10-year review of management.
        Am Surg. 2011; 77: 198-200
        • Edge S.B.
        • Compton C.C.
        The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
        Ann Surg Oncol. 2010; 17: 1471-1474
        • Capella C.
        • Heitz P.U.
        • Hofler H.
        • Solcia E.
        • Kloppel G.
        Revised classification of neuroendocrine tumours of the lung, pancreas and gut.
        Virchows Arch. 1995; 425: 547-560
        • Costes V.
        • Marty-Ane C.
        • Picot M.C.
        • Serre I.
        • Pujol J.L.
        • Mary H.
        • et al.
        Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study.
        Hum Pathol. 1995; 26: 740-745
        • Vilar E.
        • Salazar R.
        • Perez-Garcia J.
        • Cortes J.
        • Oberg K.
        • Tabernero J.
        Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
        Endocr Relat Cancer. 2007; 14: 221-232
        • Rindi G.
        • Kloppel G.
        • Couvelard A.
        • Komminoth P.
        • Korner M.
        • Lopes J.M.
        • et al.
        TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.
        Virchows Arch. 2007; 451: 757-762
        • Pelosi G.
        • Bresaola E.
        • Bogina G.
        • Pasini F.
        • Rodella S.
        • Castelli P.
        • et al.
        Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables.
        Hum Pathol. 1996; 27: 1124-1134
        • Travis W.D.
        • Rush W.
        • Flieder D.B.
        • Falk R.
        • Fleming M.V.
        • Gal A.A.
        • et al.
        Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
        Am J Surg Pathol. 1998; 22: 934-944
        • Moertel C.G.
        • Kvols L.K.
        • O'Connell M.J.
        • Rubin J.
        Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
        Cancer. 1991; 68: 227-232
        • Caplin M.
        • Sundin A.
        • Nillson O.
        • Baum R.P.
        • Klose K.J.
        • Kelestimur F.
        • et al.
        ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms.
        Neuroendocrinology. 2012; 95: 88-97